Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Show more

Location: 100 Nagog Park, Acton, MA, 01720, United States | Website: https://www.insulet.com | Industry: Medical Devices | Sector: Healthcare


Market Cap

18.18B

52 Wk Range

$230.05 - $354.88

Previous Close

$258.20

Open

$257.85

Volume

521,063

Day Range

$254.08 - $260.60

Enterprise Value

18.41B

Cash

757.4M

Avg Qtr Burn

N/A

Insider Ownership

0.28%

Institutional Own.

-

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

We track quarterly 13F filings for some of the largest biotech hedge funds here.